Louise Wang, Heena Desai, Craig Teerlink, Oliver Clark, Kathryn M Pridgen, Jennifer Lee, Kyong-Mi Chang, Rachel L Kember, Marijana Vujkovic, Julie A Lynch, Kara N Maxwell
{"title":"Cross-Ancestry and Phenome-Wide Associations of Cancer-Specific Polygenic Risk Scores.","authors":"Louise Wang, Heena Desai, Craig Teerlink, Oliver Clark, Kathryn M Pridgen, Jennifer Lee, Kyong-Mi Chang, Rachel L Kember, Marijana Vujkovic, Julie A Lynch, Kara N Maxwell","doi":"10.1200/PO-25-00957","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Genome-wide association studies have identified many common variants associated at low effect sizes with various cancers. Summing the effects of these variants into polygenic risk scores (PRS) can improve cancer risk prediction. However, cross-cancer and cross-phenotype pleiotropic associations of cancer-specific PRS are limited.</p><p><strong>Methods: </strong>Using logistic regression models, we tested the association of 13 cancer-specific PRS with curated phenotypes representing the same 13 cancers and 340 cancer and cardiometabolic phecodes in 560,287 individuals (114,255 African ancestry [AFR] and 446,032 European ancestry [EUR]) from the Million Veteran Program. Models were stratified by ancestry and used age, principal components, and cancer-specific PRS per standard deviation as independent variables, and correction was applied for multiple comparisons.</p><p><strong>Results: </strong>All 13 cancer-specific PRS were significantly associated with their respective cancers among EUR individuals with odds ratios per standard deviation of PRS (odds ratio [OR]) 1.05-1.70. Among AFR individuals, the effect sizes of the cancer PRS were lower, with OR 1.01-1.48, and cancer-specific PRS were significantly associated with their respective cancers for five of 13 cancers (bladder, breast in female patients, colorectal, prostate, and thyroid). In cancer-cancer pleiotropy studies, only the renal cancer-specific PRS was significantly associated with skin cancer (OR = 1.04, <i>P</i> = 4.5 × 10<sup>-06</sup>) among EUR individuals. PheWAS demonstrated five positive pleotropic associations with cardiometabolic conditions (thyroid cancer PRS with thyroid goiter, oral cancer PRS with diabetes phenotypes, and hypothyroidism) and two negative associations (oral and lung cancer PRS separately with coronary artery disease).</p><p><strong>Conclusion: </strong>Cancer PRS have stronger associations per cancer among EUR versus AFR individuals. In contrast to PRS of other chronic diseases, the majority of cancer-related PRS are highly specific and pleiotropic associations with other cancers and cardiometabolic traits are uncommon.</p>","PeriodicalId":14797,"journal":{"name":"JCO precision oncology","volume":"10 9","pages":"e2500957"},"PeriodicalIF":4.7000,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JCO precision oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1200/PO-25-00957","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/9/17 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: Genome-wide association studies have identified many common variants associated at low effect sizes with various cancers. Summing the effects of these variants into polygenic risk scores (PRS) can improve cancer risk prediction. However, cross-cancer and cross-phenotype pleiotropic associations of cancer-specific PRS are limited.
Methods: Using logistic regression models, we tested the association of 13 cancer-specific PRS with curated phenotypes representing the same 13 cancers and 340 cancer and cardiometabolic phecodes in 560,287 individuals (114,255 African ancestry [AFR] and 446,032 European ancestry [EUR]) from the Million Veteran Program. Models were stratified by ancestry and used age, principal components, and cancer-specific PRS per standard deviation as independent variables, and correction was applied for multiple comparisons.
Results: All 13 cancer-specific PRS were significantly associated with their respective cancers among EUR individuals with odds ratios per standard deviation of PRS (odds ratio [OR]) 1.05-1.70. Among AFR individuals, the effect sizes of the cancer PRS were lower, with OR 1.01-1.48, and cancer-specific PRS were significantly associated with their respective cancers for five of 13 cancers (bladder, breast in female patients, colorectal, prostate, and thyroid). In cancer-cancer pleiotropy studies, only the renal cancer-specific PRS was significantly associated with skin cancer (OR = 1.04, P = 4.5 × 10-06) among EUR individuals. PheWAS demonstrated five positive pleotropic associations with cardiometabolic conditions (thyroid cancer PRS with thyroid goiter, oral cancer PRS with diabetes phenotypes, and hypothyroidism) and two negative associations (oral and lung cancer PRS separately with coronary artery disease).
Conclusion: Cancer PRS have stronger associations per cancer among EUR versus AFR individuals. In contrast to PRS of other chronic diseases, the majority of cancer-related PRS are highly specific and pleiotropic associations with other cancers and cardiometabolic traits are uncommon.
目的:全基因组关联研究已经确定了许多与各种癌症在低效应量下相关的常见变异。将这些变异的影响汇总成多基因风险评分(PRS)可以改善癌症风险预测。然而,癌症特异性PRS的跨癌和跨表型多效性关联是有限的。方法:使用逻辑回归模型,我们测试了来自百万退伍军人计划的560,287名个体(114,255名非洲血统[AFR]和446,032名欧洲血统[EUR])的13种癌症特异性PRS与代表相同13种癌症和340种癌症和心脏代谢密码的筛选表型的关联。模型按血统分层,使用年龄、主成分和癌症特异性PRS每标准差作为自变量,并对多重比较进行校正。结果:所有13种癌症特异性PRS在EUR个体中与各自的癌症显著相关,每PRS标准差的比值比(odds ratio [OR])为1.05-1.70。在AFR个体中,癌症PRS的效应量较低,OR为1.01-1.48,并且癌症特异性PRS与13种癌症中的5种(女性患者的膀胱癌、乳腺癌、结直肠癌、前列腺癌和甲状腺癌)的各自癌症显著相关。在癌症-癌症多效性研究中,在EUR个体中,只有肾癌特异性PRS与皮肤癌显著相关(OR = 1.04, P = 4.5 × 10-06)。PheWAS与心脏代谢疾病(甲状腺癌PRS伴甲状腺肿、口腔癌PRS伴糖尿病表型和甲状腺功能减退)有5种正多效性关联,2种负相关(口腔癌PRS分别与冠状动脉疾病)。结论:癌症PRS在EUR和AFR个体之间具有更强的相关性。与其他慢性疾病的PRS相比,大多数与癌症相关的PRS是高度特异性的,与其他癌症和心脏代谢特征的多效性关联并不常见。